Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
Condition: Cervical Cancer Intervention: Drug: Nimotuzumab、Tislelizumab Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer
Condition: Cervix Carcinoma Intervention: Other: no intervention Sponsor: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
Condition: Cervical Cancer Intervention: Drug: Nimotuzumab、Tislelizumab Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer
Condition: Cervix Carcinoma Intervention: Other: no intervention Sponsor: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
Condition: Cervical Cancer Intervention: Drug: Nimotuzumab、Tislelizumab Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer
Condition: Cervix Carcinoma Intervention: Other: no intervention Sponsor: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
Condition: Cervical Cancer Intervention: Drug: Nimotuzumab、Tislelizumab Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer
Condition: Cervix Carcinoma Intervention: Other: no intervention Sponsor: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
Condition: Cervical Cancer Intervention: Drug: Nimotuzumab、Tislelizumab Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer
Condition: Cervix Carcinoma Intervention: Other: no intervention Sponsor: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer
Condition: Cervical Cancer Intervention: Drug: Nimotuzumab、Tislelizumab Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
System to Evaluate the Risk of Lymph Node Metastasis Preoperatively in Cervical Cancer
Condition: Cervical Cancer Intervention: Procedure: surgery Sponsor: Fujian Maternity and Child Health Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2023 Category: Research Source Type: clinical trials
